Introduction
Calcitonin has been used for some years for Paget's disease of bone. ' 3It prevents extension of the disease and induces radiological healing.4 -Long-term or even lifelong treatment may be necessary in patients whose disease is potentially crippling,-or in those with spinal cord compression 8 or high-output cardiac failure. 9 The only hormones available commercially so far, porcine and salmon calcitonin, differ appreciably from human calcitonin in their amino-acid sequence."'' They are antigenic in man, and resistance developing during treatment has been ascribed to these antibodies." 12 
Results
In the first few months of treatment urinary hydroxyproline concentrations fell in all patients. They reached a plateau, as indicated by the grouped data in fig 1. Fig 2 shows details of three patients, in one of whom urinary hydroxyproline returned to pretreatment concentrations despite continued calcitonin treatment and a high antibody titre. A small rebound increase in hydroxyproline occurred in the other two patients.
During treatment (mean duration 29 months) antibodies were detected in 11 of the 16 patients (69°0) In a larger series of assays carried out on patients from several centres (to be published), the overall incidence was about 45 ', after six months' treatment. Antibodies developed within 3 to 18 months and increased rapidly in titre in four patients (fig 3) . Antibody titres fell in nine patients during treatment, and levels in three of them eventually fell below a serum dilution of 1/50. The acute calcium-lowering effects of salmon and human calcitonin were tested in eight patients, six of whom had antibodies to salmon calcitonin. In two patients a calcium-lowering response was obtained with human but not with salmon calcitonin (fig 4) . Both of these patients had high anti-salmon calcitonin titres, but only one (case 12) had evidence of resistance to long-term treatment with salmon calcitonin (fig 2) . The other patient (case 16) maintained low serum alkaline phosphatase concentration and urinary hydroxyproline excretirn 24 months after first developing an antibody titre of 1/3200.
Discussion
These findings draw attention to the high incidence of antibody formation during treatment with salmon calcitonin. Clinical and biochemical improvement occurred and was maintained in spite of these antibodies, which were observed in variable titres at some stage during treatment in over half the patients. In Conversion: SI to traditional units-Calcium: 1 mmol/l 4 mg/100 ml. some cases the antibodies appeared transiently and in others their titres fell appreciably during treatment.
In most patients hydroxyproline excretion was maintained at a plateau level during treatment. One patient (case 12) showed a biochemical relapse, and her urinary hydroxyproline excretion returned to pretreatment levels. This woman had gross skull disease, worsening neurological damage, and high antibody titres. Furthermore, she responded to an acute injection of human, but not salmon calcitonin, with a prompt fall in serum calcium concentration. Although this might suggest that her biochemical relapse had occurred as a result of neutralisation of hormone activity by antibody, an almost identical relapse has been observed in a similarly affected patient treated with human calcitonin,14 and, furthermore, the biochemical relapse in case 12 did not occur until almost two years after development of an antibody titre of 1/6400 (figs 2 and 3). The 
Summary
We examined the plasma urea and creatinine concentrations and the ratio between them according to diagnosis in 100 unselected and 31 selected adult hospital patients with a plasma urea concentration > 10 mmol/l (60 mg/100 ml). We also examined plasma urea and creatinine concentrations in 350 unselected consecutive patients, but found no useful relation between the two values.
Congestive heart failure was the most common identifiable cause of a raised plasma urea concentration in the 100 unselected patients (36%). Among these 100 patients the plasma creatinine concentration was a more useful discriminant between prerenal uraemia and intrinsic renal failure than was the urea:creatinine ratio or the plasma urea concentration.
A plasma creatinine concentration > 250 tmol/l (2-8 mg/100 ml) indicated intrinsic renal failure with a 90 % probability. 
Introduction
Measurement of the plasma urea concentration is still the usual screening test for renal glomerular failure, but it is generally recognised that the failure must be gross before the plasma urea concentration is clearly raised, and that it may be raised for reasons other than glomerular failure. It has been stated that the causes of a raised plasma urea concentration can be distinguished by measuring the plasma creatinine concentration and calculating the ratio of the two values. '-4 Two reasons prompted us to re-examine the diagnostic role of measuring plasma creatinine concentrations and the urea: creatinine ratios. Firstly, the introduction of multichannel analysers has made measurements of plasma creatinine concentrations more generally available, and they are often made when they are not requested. Hence the urea:creatinine ratio is probably being increasingly used as an aid to interpret a raised plasma urea concentration. Furthermore, we were surprised to find that the publications which support the use of the urea: creatinine ratio contain little detailed information, and the conclusions seem to be based more on physiological principles than on a study of the usefulness of the ratio in clinical practice.
As a first step in the re-examination of this problem we studied the relation between plasma urea and plasma creatinine values in 350 consecutive patients in whom the two measurements had been made on the same blood sample. Secondly, we studied the case histories of 100 consecutive patients with a plasma urea concentration . 10 mmol/l (60 mg/100 ml) who had creatinine measured on the same plasma sample. We also examined the records of an additional 17 consecutive patients with acute intrinsic renal failure and 14 consecutive patients with chronic renal failure to increase the size of the groups with these disorders. We examined the plasma urea and creatinine values and the ratio between them according to the cause of the raised plasma urea concentration. In the larger
